

Dear Jing Yu:

Thank you very much for your decision letter and advice on our manuscript (Manuscript No.: 19615) entitled “**The new role and molecular mechanism of Gadd45a in hepatic fibrosis**”. We also thank the reviewers for their constructive and positive comments and suggestions. Accordingly, we have revised the manuscript according to the Guidelines of *World Journal of Gastroenterology*. In addition, the point-by-point responses to the comments are listed below this letter.

This revised manuscript has been edited and proofread by *Medjaden* Bioscience Limited.

We hope that the revision is acceptable for publication in your journal, and we look forward to hearing from you soon.

Yours sincerely,

Ji-Guang Ding

Comments To Authors

Title: **The new role and molecular mechanism of Gadd45a in hepatic fibrosis**

Reviewer's code: 02439020

Date sent for review: 2015-05-15

Date reviewed: 2015-05-29

Dear Dr. Liang Hong,

Thanks for submitting your manuscript to WJG. This is an interesting study and bring fresh idea in signal transduction of hepatic fibrosis. However, I would suggest the authors to carry out a revision on the present manuscript before it can be accepted for publication in WJG.

My specific comments are as follows:

1. The grouping is too simple. It will be better if inhibitor group is added.

Response: We agree with the reviewer that it would be better to include an inhibitor group. However, we cannot obtain the appropriate commercial inhibitor at present. Moreover, siRNA exerts a similar function as does an inhibitor. Therefore, we did not add an inhibitor group in the revised version.

2. More fresh references within 5 years are more persuasive.

Response: Five new references within the past 5 years have been added.